- 24/7 Wall St.•2 days ago
Some companies are hitting lows and creating huge shareholder losses while the market is just below all-time highs but still struggling. These are the same companies holding back the market and punishing ...
- Benzinga•4 days agoPuma Biotech, Which Had Weak Demand For A Secondary Offering, Is Also Part Of The SEC Tick Size Pilot Program
Puma Biotechnology Inc (NYSE: PBYI ) has had one of its most volatile weeks in recent memory thanks to weak demand for a secondary offering. falling over 28 percent from its Tuesday high of $54.65 To ...
- Business Wire•4 days ago
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the underwriters for its public offering of 3,750,000 shares of its common stock at $40.00 per share have elected to exercise in full their option to purchase up to an additional 562,500 shares of common stock at the public offering price, less the underwriting discounts and commissions.
Puma Biotechnology, Inc. (PBYI)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||43.20 x 100|
|Ask||43.50 x 400|
|Day's Range||42.55 - 44.40|
|52wk Range||19.74 - 94.93|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.53|
|Avg Vol (3m)||1,057,080|
|Dividend & Yield||N/A (N/A)|